TransMedics: Despite Earnings Miss, Growth Story Remains Intact (NASDAQ:TMDX)
· seekingalpha.com
TransMedics (TMDX) is still rated a Strong Buy after a 50% drop and Q1 miss—see growth drivers, Europe rollout, guidance, and margin targets. Read the full analysis here.
Since my last bullish article , TransMedics is down nearly 50%. So far in 2026, TransMedics is down
I am a CPA and financial consultant with over two decades o...